Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis inhibitors have been the cornerstone of advanced hepatocellular carcinoma treatment, but the introduction of novel therapies and immune checkpoint inhibitor-based combinations is driving the sales growth. The extension of these agents into early-stage settings and the anticipated entry of new immune checkpoint inhibitor-based combinations will further enhance the availability of effective treatments and boost sales. The late-phase pipeline for hepatocellular carcinoma in China is particularly strong; Akeso’s penpulimab and Junshi’s Tuoyi (toripalimab) are awaiting approval in the first-line setting. This report analyzes how clinical and nonclinical factors—such as pricing dynamics and inclusion in China’s National Reimbursement Drug List—will influence the treatment of hepatocellular carcinoma during the forecast period. Understanding these converging factors will be crucial for the success of both current and future players in this highly competitive market.
QUESTIONS ANSWERED
- What is the diagnosed incidence of hepatocellular carcinoma in China? Are there any differences in the management strategies in urban vs. rural China?
- What are interviewed experts’ insights into current treatment options? What are the key unmet needs in the management of hepatocellular carcinoma?
- What are the most promising agents in the pipeline, and how will they shape the future of this market in China?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
- What are the key drivers of and constraints in this therapy market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
Release Date
October 2025
Geographies
China
Primary Research
Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 medical oncologists in China
Epidemiology
Diagnosed incidence of hepatocellular carcinoma in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
Forecast
10-year, annualized, drug-level sales and patient share of key hepatocellular carcinoma therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions
Drug treatments
Coverage of key current and late-phase emerging therapies
Custom drug modeler
Integrated tool to input customized forecast assumptions (e.g., launch date, price)
